Anakinra (KineretR) is a humanized IL-1 receptor antagonist and Canakinumab (IlarisR) is an anti-IL-1B monoclonal antibody.[63,64] They haveshown effectiveness in uveitis associated with BD and MS.[65,57,68] Adverse reactions to this group ofmedications include injection site reactions, anaphylaxis, and infections such aspneumonia.[69]. This evidence concerns the gene IL1B and uveitis.